1. Germany Stocks

  2. •

    Health services

  3. •

    Hospital/Nursing management
NanoRepro AG

NanoRepro AG

1.68
EUR
-0.08
(-4.83%)
19.30MMarket Cap
May 14Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.82
0.31
0.19
0.12
0.26
0.24
0.27
0.14
1.82
12.62
3.02
0.26
0.37
- -
Basic EPS, GAAP
-0.51
-0.15
-0.01
-0.26
-0.09
-0.1
-0.03
-0.14
0.18
2.3
-0.29
-0.37
-0.16
- -
Free Cash Flow per Basic Share
- -
-0.23
-0.23
-0.21
-0.13
-0.16
-0.03
-0.07
-0.12
0.64
0.76
-0.81
0.75
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.5
0.15
- -
- -
Book Value per Share
0.34
0.49
0.57
0.5
0.51
0.54
0.65
0.51
0.86
4.46
3.68
3.18
3.02
2.96
Tangible Book Value per Share
0.25
0.27
0.15
0.15
0.21
0.26
0.41
0.24
0.85
4.46
3.42
2.91
2.76
2.69
Basic Weighted Avg Shares
1
3
3
5
6
7
9
9
9
13
13
13
13
13
Sales/Revenue/Turnover
1
1
1
1
2
2
2
1
17
163
39
3
5
- -
Operating Margin (%)
-62.67
-46.96
-3.99
-220.67
-68.6
-38.19
-13.62
-93.49
27.62
24.28
13.98
-136.82
-74.23
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
2
- -
- -
- -
- -
- -
Net Income, GAAP
-1
- -
- -
-1
-1
-1
- -
-1
2
30
-4
-5
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
39.05
23.31
- -
- -
- -
- -
Profit Margin (%)
-62.99
-47.34
-4.31
-220.77
-35.64
-43.64
-12.22
-96.01
10
18.26
-9.55
-144.31
-44.02
- -
Working Capital
1
1
1
1
1
2
4
2
9
68
45
35
15
10
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
2
2
2
3
4
6
4
8
58
47
40
38
37
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
23.38
86.32
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
24.43
88.71
- -
- -
- -
- -
Return on Common Equity (%)
-68.48
-39.74
-1.52
-56.25
-20.78
-21.41
-6.13
-23.66
27.3
90.62
-7.09
-10.67
-5.21
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
21
17
19

Working Capital

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
31
15
10
Cash, Cash Equivalents & STI
26
9
7
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
76.78%
132.67%
-5.53%
Free Cash Flow
-102.55%
-227.41%
-192.15%
Net Income, GAAP
575.28%
253.6%
-56.34%
Sales/Revenue/Turnover
218.24%
400.97%
43.15%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3
2024
- -
- -
5
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.37
2024
- -
- -
-0.16
2025
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.15
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lisa Jüngst
Full Time Employees
22
Sector
Health services
Industry
Hospital/Nursing management
Address
Untergasse 8 Marburg HE Germany 35037
IPO Date
Oct 9, 2012
Website
nano.ag
Similar Companies
Apollo Hospitals Enterprise Limited (NSE:APOLLOHOSP)
Max Healthcare Institute Ltd (NSE:MAXHEALTH)
Fortis Healthcare Ltd. (NSE:FORTIS)
Bangkok Dusit Medical Services Public Co. Ltd. (SET:BDMS)
Yatharth Hospital and Trauma Care Services Limited (NSE:YATHARTH)
HCA Healthcare, Inc. (NYSE:HCA)
Business
NanoRepro AG (NN6.DE) develops, manufactures, and distributes CE-marked rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers immunochromatographic lateral flow tests in categories including family planning (pregnancy, ovulation, menopause, and male fertility tests such as OvuQUICK, GraviQUICK, MenoQUICK, and FertiQUICK); preventive healthcare and disease detection (gluten intolerance, Helicobacter pylori, vaginal yeast, iron deficiency, occult blood in stool, cholesterol levels, vitamin D, and breath alcohol); infectious diseases and allergies (streptococci antigen, influenza A/B, aids, troponin I, D-dimer, candida, and SARS-CoV-2 antigen/antibody tests); and drug screening; alongside food supplements like Alphabiol Beauty Elixier, Alphabiol Fertility, and Alphabiol Curcumin Elixier. Founded in 2006 and publicly listed since October 2008, NanoRepro AG is headquartered in Marburg, Germany, and operates primarily in the biotechnology and diagnostics sector with approximately 23 employees targeting consumers, pharmacies, hospitals, and medical practices. In recent developments, the company acquired a 50.03% majority stake in Paedi Protect AG and a 33% stake in hyped about science GmbH to expand its health and lifestyle portfolio; invested in cold plasma technology and planned a 37.5% stake in terraplasma medical GmbH; secured EU quality management certification under Regulation (EU) 2017/746 for in-vitro diagnostics; reported 75% core business revenue growth in 2024 with strong half-year results; launched new products including ZuhauseTEST Vitamin D and an RSV/influenza/SARS-CoV-2 combo antigen test; and confirmed CEO Lisa Jüngst while pursuing strategic growth in self-diagnostics amid post-COVID market shifts.